Jiangchuan Macrolide Facility Update

CHENGDU, China, July 16 /PRNewswire-Asia-FirstCall/ —
Tianyin Pharmaceutical (NYSE Amex: TPI), a pharmaceutical company that specializes in
patented biopharmaceutical, modernized traditional Chinese medicine
and branded generics provides progress update on its Jiangchuan
macrolide facility.

The construction of the facility is on schedule, targeting
August for completion and equipment installation, immediately
followed by GMP certification and trial production. The
state-of-the-art macrolide facility, occupying 100mu (~16.5 acres)
of land at Sichuan Xinjin Industrial Park near Chengdu, is designed for a total annual
capacity of 240 tons of macrolide Active Pharmaceutical Ingredients
(API) to serve the growing macrolide antibiotics market.

Jiangchuan macrolide initiative, established in 2009, is
designed for the research and development, manufacturing and sales
& marketing of API and chemical intermediates of macrolide
antibiotics for Azithromycin, Clarithromycin, and
Roxithromycin.

Dr. Jiang Guoqing, CEO of Tianyin Pharmaceutical pointed out,
“Jiangchuan macrolide initiative expands our scope of business into
the large arena of antibiotics. Jiangchuan is not only of great
strategic significance and sustainable economic benefits, but also
projected to become a leading manufacturer of macrolide antibiotics
in China. It captures the growth
momentum created by the ongoing healthcare reform. The steady
increase of the macrolide raw material prices reaffirmed our market
forecast. Additionally, the API business has an efficient profit
chain that consists of three key elements: 1) raw material pr

‘/>”/>

SOURCE